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Abstract: This article reviews the development of the Ninth Clinical Consensus Statement by
SIBEN (the Ibero-American of Neonatology) on “Early Detection with Pulse Oximetry (SpO2) of
Hypoxemic Neonatal Conditions”. It describes the process of the consensus, and the conclusions and
recommendations for screening newborns with pulse oximetry.
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1. Introduction and Methodology
For many years, the education, training, and advances in neonatology in Spanish and Portuguese
speaking countries have been inconsistent—although this is also probably true for many countries.
In 2004, the Ibero-American Society of Neonatology (SIBEN) was created, with the principal objective
of contributing to the improvement of the quality of life for newborn infants and their families in the
Ibero-American population. SIBEN is a new society, with members from 29 different countries that
focuses on neonatology facilitating education, communication, and professional advancement that
contributes to the welfare and well-being of newborns and their families, in order to improve neonatal
outcomes in the region. Over the past years, it has been demonstrated that the process of medical
consensus could be a way of increasing professional collaboration, as well as improving uniformity
in the care given to newborn infants. In 2007, SIBEN began annual meetings of a Clinical Consensus
Group, where we—under the guidance of an expert or opinion leader in the topic—organized several
subgroups of neonatal professionals in the Ibero-American region. Each subgroup critically reviews
all the available literature in order to find the answers to several questions that had been posed
to them. SIBEN’s consensus process is the first of its kind in the region. It has led to active and
collaborative participation of Ibero-American neonatologists of 19 countries and has significantly
improved education of all participants. At SIBEN, we believe that the critical review and summary
of available clinical data as well as the recommendations made by the SIBEN consensus contribute
to consistent best practice for newborn care and develops a useful foundation and valuable model
to reduce the gaps in knowledge and the clinical care every newborn baby receives in in this region,
thus decreasing the disparity in the care provided and improving short and long-term outcomes.
Several important neonatal topics, all relevant to neonatal clinical practice, have been covered so far
by SIBEN’s clinical consensus including patent ductus arteriosus (PDA), hemodynamic management,
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bronchopulmonary dysplasia (BPD), hematology, nutrition, persistent pulmonary hypertension of the
newborn (PPHN), and hypoxic ischemic encephalopathy, which have been published in consensus
statements and peer reviewed journals. This paper is a summary of SIBEN’s consensus statement on
newborn screening with pulse oximetry.
2. Background on Screening for Congenital Heart Disease
The prevalence, epidemiology, and impact of delay in the diagnosis of CHD have been described
in several publications [1–8]. Critical congenital heart defects (CCHD) affect approximately 2 out of
every 1000 live births; it is estimated that about 40,000 babies are born with CCHD per year in the
US, and 1.35 million worldwide, including ductus-dependent lesions. CCHD represent about 40%
of deaths due to congenital malformations and the majority of deaths from cardiovascular disease
occurring in the first year of life. It is known that more than 30% of CCHD deaths have been attributed
to errors in diagnosis or late diagnosis [9]. For example, in UK it was estimated that 25% of congenital
heart disease defects are not diagnosed until after discharge from hospital, and newborns may become
seriously ill or die. It is now understood that prenatal or postnatal examination is inadequate for the
early detection of these potentially lethal and treatable conditions. Delay in the diagnosis of CCHD
may increase the risk of death or permanent injury in newborn babies [10,11].
In 2009, de-Wahl Granelli et al. [12] published a cohort study in which 39,821 children had
oxygen saturation measured by pulse oximetry (SpO2) in the upper and lower extremities and
demonstrated acceptable test accuracy for the detection of CCHD. Ewer et al. [13], in a similar study
in 20,055 asymptomatic newborns, reported similar findings and Zhao and colleagues [14] in China
studied 100,000 newborns and demonstrated the same.
In 2011, the US Advisory Committee on Heritable Disorders in Newborns and Children Advisory
Committee on Hereditary Diseases [15–17] found that there was sufficient evidence to recommend
screening with pulse oximetry [1–64]. The heart defects that can be detected early are mainly the
following specific lesions: hypoplastic left heart syndrome, pulmonary atresia, tetralogy of Fallot,
anomalous pulmonary venous return, transposition of large vessels, tricuspid atresia, and truncus
arteriosus. Screening can also detect: interrupted aortic arch, critical aortic stenosis, aortic valve
stenosis, pulmonary valve stenosis. In addition, pulse oximetry screening is useful for the early
detection of other conditions with neonatal hypoxemia, such as respiratory disorders (e.g., congenital
pneumonia, meconium aspiration, pneumothorax, transient tachypnea of the newborn), neonatal
sepsis, and pulmonary hypertension. These findings and others were summarized in a meta-analysis
and systematic review by Thangaratinam and colleagues [18].
3. SIBEN’s Consensus on Screening with Pulse Oximetry: An Overview
Based on the issues described above, we proceeded to organize the Ninth Clinical SIBEN
Consensus on “Early Detection with Pulse Oximetry (SpO2) of Neonatal Hypoxemic Conditions”.
The concern about the late diagnosis of CCHD led to the investigation of early detection with SpO2
screening. These screening programs have detected other conditions that also present with hypoxemia
in addition to CCHD that would have been diagnosed later if not for the evaluation with SpO2 [19].
In order to make recommendations for the Ibero-American region to implement programs pulse
oximetry screening, 39 neonatologists and 4 neonatal nurses from 18 Ibero-American countries were
invited to participate and to collaborate. They worked for several months with an intense and
collaborative methodology, and met in person at San José de Costa Rica, in September 2015, during the
Annual SIBEN Conference. Professor Andrew Ewer from the UK was the leader and expert opinion
for this ninth SIBEN’s Consensus. Neonatal hypoxemia, such as it occurs in critical congenital heart
disease (CCHD) and other conditions, is an abnormal situation, potentially fatal if not diagnosed or
if diagnosed late, PO screening allows earlier detection and thus the opportunity to optimize their
management and improve outcomes.
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Several questions of clinical significance were developed on the early detection with SpO2 of
diseases that present with neonatal hypoxemia. They included:
1. Cyanosis and related concepts.
2. What is hypoxemia?
3. What is hypoxia?
4. What is pulse oximetry, and what are the normal values in a healthy term newborn?
5. What is the hemoglobin dissociation curve?
6. How does altitude influence on the SpO2?
7. Which are the lesions that can be detected early?
8. How should you do the screening?
9. What are normal and abnormal results?
10. What are false positive and false negative results?
11. How should you interpret the pre- and post-ductal SpO2 difference?
12. What should we do with an apparently healthy newborn that fails the screening?
13. How should we take care of the family of a newborn that has either a positive or negative screening?
14. Is this program cost-effective?
15. When should we order an echocardiogram?
16. Importance of the information and participation of the healthcare team—what data should
you record?
17. Who should do the screening?
18. What limitations does pulse oximetry have?
19. What role can the Perfusion Index (PI) have during the screening?
The subgroups were tasked with answering 2–4 of the above questions. They methodically
searched and reviewed the available literature, then interacted and worked together as a whole group
to find consensus for the answers to all the questions. This SIBEN Clinical Consensus Group concluded
that pulse oximetry is a non-invasive method that allows the rapid measurement of saturation of
hemoglobin in arterial blood that can detect hypoxemia in asymptomatic and apparently healthy
newborns who suffer from severe health conditions such as critical congenital heart disease. In addition
to CCHD, the following conditions can be diagnosed early with SpO2 screening:
• Early sepsis
• Congenital pneumonia
• Pulmonary hypertension
• Meconium aspiration
• Transient tachypnea
• Pneumothorax
• Other various less frequent neonatal conditions
The early use of pulse oximetry in apparently healthy babies is simple, very easy to perform, fast,
non-invasive, cost effective [20,21], and provides a significant improvement in quality and safety in
neonatal healthcare. Thus, SIBEN recommended that programs of early detection or screening with
SpO2 are implemented in all places where neonatal care is delivered in Latin America. In summary,
the early evaluation of all the newborns with SpO2 is a complementary, non-invasive, easy-to-perform,
and low cost test that is performed between 12–48 h of life and is of great clinical utility to detect
potentially serious diseases in asymptomatic and apparently healthy newborn infants. The universal
implementation of this evaluation in clinical practice leads to a narrowing of the diagnostic gap for
newborns to increase patient safety and to reduce the morbidity, sequelae, and mortality of these babies.
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4. SIBEN’s Consensus on Screening with Pulse Oximetry: A Summary
We summarize answers to some of the specific questions and recommendations below.
4.1. Evaluation with SpO2 Monitors and Sampling Sites
Neonatal screening for the detection of pathologies associated with hypoxemia has been
introduced in clinical practice in the USA since 2011. Since then, studies and meta-analysis [18]
show that it meets the criteria for population screening test, as well as being a tool in the early
and timely diagnosis of severe neonatal conditions. Nevertheless, it is still not universally used in
Latin America and work was needed to identify protocols. The SpO2 screening technique is very
easy to perform, and should be performed in all apparently healthy newborns between 12–48 h
after birth (see below) or before discharge. It should be done by placing a sensor in the palm of the
right hand (pre-ductal) and then another in one of the lower limbs (post-ductal). SpO2 readings are
taken and recorded from the two sites, one after the other (it is not necessary to use two monitors
simultaneously). Screening has to be done with both pre- and post-ductal measurements because some
heart defects with obstruction of the left output tract may not be diagnosed when performing a single
post-ductal measurement.
The published evidence is clear in relation to the quality of the signal. The SIBEN consensus
concludes that evaluating the quality of the signal is fundamental to being able to interpret that the
SpO2 readings are correct. Therefore, the screening must be performed with a SpO2 monitor that
functions in low perfusion states and is not subject to motion artefact.
4.2. Clinical Protocol
Based on the SIBEN clinical consensus, it is recommended that this SpO2 screening method (pre
and post ductal) be performed in all healthy newborns between 12 and 24 h of life, or before discharge
home if the discharge is prior to that age. If the first pre- and post-ductal SpO2 measurements are both
95–100% with <3% difference between them, the evaluation is normal and the newborn has a negative
screening test. If the first measurement is positive/abnormal (SpO2 90–95% and/or difference >2%)
and the infant looks healthy, the pre- and post-ductal measurements must be repeated once more,
according to the protocol chosen by SIBEN, described in Figure 1 below. In infants with clinical
symptoms or when SpO2 is <90%, prompt admission to NICU and further evaluation should be
initiated without delay.Int. J. Neonatal Screen. 2018, 4, x FOR PEER REVIEW  5 of 10 
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A second measurement is only done if the first one is positive (abnormal) and if the infant
continues to appear completely healthy. If the infant has any clinical signs, they should be admitted,
as would any sick neonate for any other reason. The second evaluation should be done 15–30 min
after the first in order to reduce delay. Furthermore, if the infant was sound asleep during the first
evaluation, they should be alert for the second. If the second measurement is normal, the test is
considered normal, that is to say that the screening is negative. If first and second evaluations are
positive, and/or if the infant has any clinical signs, immediate admission to NICU is recommended.
If the infant appears healthy, they should be carefully assessed as described below.
4.3. What to Do with a Neonate Who Appears Clinically Healthy but Has Abnormal or Positive SpO2?
Do not ignore the test and humbly accept that we may be wrong in our clinical assessment.
It is necessary to evaluate quickly, in a detailed and complete approach, every newborn who has
an abnormal test result with SpO2. The absence of a murmur, normal blood pressure, or the presence
of normal femoral pulses do not rule out a critical congenital heart disease. In addition, in infectious
conditions or other hypoxemic conditions there will be no heart murmur and the other parameters
may well be normal initially. If the diagnosis is not clear, other studies should be carried out for timely
diagnosis, including frequent or continuous assessment of pre- and post-ductal SpO2. According to
the clinical suspicion, a complete diagnostic approach and may include complete blood count, cultures,
blood gases, and chest X-rays. Some will require an echocardiogram, and in some it will be necessary
to immediately start an infusion of prostaglandin to maintain patency of the ductus arteriosus.
4.4. Concept of False Positive and False Negative Screening
As mentioned, an infant with a positive screening test has one SpO2 < 90% or two consecutive
tests with SpO2 90–95% and/or pre-post ductal difference >2%. A false positive result is when the
infant is found NOT to have CCHD. This occurrence is extremely rare (<0.1%) if the screening method
and protocol are followed rigorously—although it may be up to 1% [22]. If the evaluation with SpO2 is
done before 12 h of age there are slightly more false positives but diagnosis of infectious and respiratory
causes of hypoxemia are more common. A false negative is when the evaluation with SpO2 is normal
(negative screening) but the infant is actually found hours or days later to actually have CCHD. As it
can be easily understood, a false negative would be a significant issue. Most studies indicate that the
most frequently undiagnosed lesions are left sided obstructed lesions with obstruction to the outflow
of the aorta (e.g., coarctation of the aortic arch, hypoplastic left heart, aortic stenosis) which are not
necessarily associated with hypoxemia. False negatives can also occur when not using appropriate
technology. The use of the preductal and postductal saturation difference and the perfusion index
improve detection, but they are not infallible either.
4.5. Altitude and Neonatal SpO2 Screening
This is a topic that was addressed extensively, including physiology and alveolar gas equation.
SIBEN’s consensus found that, on average, SpO2 values are not different in the first 12–24 h of life in
infants born at less than 2500 m (about 8200 feet) above sea level. Therefore, if screening is done as
mentioned and at the age recommended here, the values for positive and negative results could be
kept the same. The issue is that the mean normal SpO2 is a bit lower at higher altitude (93–96%) but
with larger standard deviations. Therefore, some totally normal babies can have SpO2 of 91–94% at
>2700 m above sea level. So, more detailed observation would be recommended for asymptomatic
infants, exercising caution and avoidance of aggressive investigations in order to prevent increasing
the number of false positives. Still, exact cut-off points in moderate and high altitudes are not precisely
known to adequately balance sensitivity with false positive rates.
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4.6. Care of the Family with an Abnormal or Positive Screening
In the first hours after birth, various events generate great emotional tension. Health care
providers should make an effort to decrease this by all possible means. Families should always
actively participate in the care of their newborn infant and they should also be involved during SpO2
screening. As this can be stressful for some parents, every effort should be made so that they clearly
understand what is being done to their babies and why. Studies have shown that parents who have
been well informed are mostly satisfied with the SpO2 screening test and have perceived the screening
as valuable test to detect sick babies. In addition, parents of neonates who had a false positive result
did not show greater anxiety than those with negative or normal screenings [23].
It is recommended that parents of apparently normal newborns receive written information on the
SpO2 screening test. This written information must be accompanied by clear verbal information and
clarification of any doubts that may have arisen with the information received. It is also recommended
that the screening is performed with the parents present. In the face of a positive result, appropriate
information and support is essential throughout.
5. Summary and Discussion
We have reviewed the evidence in a formal process of clinical consensus and presented the
available data that demonstrates that early evaluation with pulse oximetry in apparently healthy
newborns does easily detect asymptomatic newborns with severe health conditions, such as critical
congenital heart disease, respiratory disorders, neonatal sepsis, persistent pulmonary hypertension,
and other hypoxemic pathologies. The objective of implementing systematic protocols in clinical
practice for the screening of all newborns by early pulse oximetry is to detect pathologies with early
hypoxemia and to perform a therapeutic approach without delays. The consensus group of SIBEN,
concludes that adequate early monitoring of SpO2 in apparently healthy newborns is useful for early
detection of several neonatal conditions which evidence has shown that the diagnosis is sometimes
untimely or late. It was estimated that about 2000 neonates died or were diagnosed late each year
in the US, and that around 300,000 babies per year die worldwide because of this. The number of
undiagnosed cases in developing countries is higher than in developed nations and it is estimated that
less than half of the cases of CCHD are diagnosed in the first week of life. The prenatal diagnosis of
CCHD can improve perinatal outcomes for certain lesions [54,55]. Recent evidence shows that CCHD
detection has progressively increased from 2006 to 2012, but also that prenatal detection is highly
variable in different countries [56]. In some cases, the diagnosis of fetal CCHD is made to later see
that the newborn is healthy. Repeated prenatal ultrasounds are much more difficult and costly than
simple SpO2 screening. Early diagnosis of CCHD in postnatal life significantly decreases morbidity
and mortality rates [24].
The effectiveness of screening is also shown in recent publications on home births in The
Netherlands [58], as well as other very comprehensive reviews [59–61]. Adding detailed physical
examination to early evaluation with SpO2 increases significantly early diagnosis of hypoxemic
neonatal conditions. SIBEN underscores that neonatal screening with SpO2 for the specific diagnosis
of early CCHD does not, of course, replace prenatal detection or clinical examination but is a very
useful complement. Accurate prenatal ultrasound, physical examination, and SpO2 screening may
increase CCHD detection rates to more than 90–95%. One of SIBEN’s recommendations is that, at the
beginning of this screening program each center must use a clearly defined protocol (as described
previously) and at least one quality indicator e.g., performing a random evaluation every 1–2 weeks
of the number of babies with screening indication (infants that should have been evaluated) and
verified that the program has been met 100% of the time. If this is not the case, processes need to
be improved in order to meet the objective of the evaluation and detection of all newborn infants.
The quality indicators are not only for CCHD but also for early detection of respiratory or infectious
conditions. Physicians should be aware that, even though the combination of early detection with
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pulse oximetry with other methods of evaluation reduces errors and diagnostic errors, some babies
can still be discharged without proper diagnosis.
Early detection of CCHD and hypoxemic neonatal conditions not only reduces the suffering of
children and families, but it can also reduce associated costs and long-term neurological compromise
by not delaying admission to a specialized care unit. This is also associated with significant
reductions in mortality, better surgical outcomes, less prolonged ventilation, and diminished potential
developmental problems. For all of the above, actively addressing the neonatal screening of CCHD
and neonatal hypoxemic conditions can achieve a significant improvement in the quality and safety of
health care, as well as cost savings. In addition, and of significant importance, the screening with pulse
oximetry in the newborn has been shown to detect hypoxemia in newborns with severe conditions
other than CCHD—such as respiratory problems, sepsis, and persistent pulmonary hypertension.
We conclude, together with many other authors, that significant deaths and morbidity can be
avoided or significantly reduced if hospitals adopt SpO2 screening for early and timely detection of
CCHD and other hypoxemic conditions [46,57–62]. Its implementation will benefit many newborns in
Latin America, where it is estimated that 60% of neonatal deaths are preventable [63,64].
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